ArticleTranslational lung cancer research2026
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidermal growth factor receptor exon 20 insertion mutations (EGFR ins20) constitute a distinct entity among Methods: Retrospective analysis of 80 patients with non-small cell lung cancer and EGFR ins20 mutations seen from 2014-2024 at a large institution and network sites to characterize patterns of metastasis and progression. Clinical outcomes were analyzed with overall survival (OS). Magnetic resonance imaging was used to assess central nervous system disease location and progression. Results: About 36.25% of the patients had progression in central nervous system with 7.5 % of patients having leptomeningeal disease. Patients with CNS progression had a similar median OS of 45.3 months (31.6-78.5 months) compared to patients without progression of 47.8 months [36.8, not estimated (NE)] with a hazard ratio of 1.21 [95% confidence interval (CI): 0.66-2.23, P=0.54]. Co-TP53 mutation was associated with lower median OS of 31.6 months (20.4-NE) compared to 47.8 months (42.8-72.3) in TP53 wild type; hazard ratio 1.79 (95% CI: 0.89-3.60, P=0.11). Conclusions: While progression in the central nervous system did not impact clinical outcomes in this patient population, the high rate of disease in the central nervous system does warrant consideration and tailoring treatment with central nervous system penetration. This subgroup continues to behave as a distinct population and as such requires unique treatment and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.